Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 25;8(5):809–815. doi: 10.7150/jca.17536

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Overall survival (OS) and progression-free survival (PFS) curves of 209 metastatic nasopharyngeal carcinoma patients with different pretreatment values of the albumin-to-alkaline phosphatase ratio (AAPR). (A). The median OS was 24.3 ± 1.4 months (95% confidence interval: 21.6-27.0) in the AAPR ≥ 0.447 group and 17.3 ± 1.4 months (95% CI: 14.6-20.0) in the AAPR < 0.447 group (χ = 33.287, P < 0.001). (B) The median PFS was 8.4 ± 0.4 months (95% confidence interval: 7.6-9.1) in the AAPR ≥ 0.447 group and 5.9 ± 0.8 months (95% CI: 4.4-7.4) in the AAPR < 0.447 group (χ = 12.139, P < 0.001).